How Long Does Rinvoq Take to Work?
Rinvoq (upadacitinib) typically begins working within 1-2 weeks, with most patients experiencing noticeable improvements by week 2-4, and maximal benefits achieved by weeks 12-16 depending on the condition being treated.
Onset of Action by Condition
Atopic Dermatitis (Fastest Response)
- Itch relief begins within 1 week: In clinical trials, 11.2% of patients on 15 mg and 17.7% on 30 mg achieved ≥4-point improvement in itch scores by week 1, compared to only 0.5% on placebo 1
- Peak itch response by weeks 4-6: Response rates continued improving through weeks 4-6 and were maintained through week 16 (47.1% for 15 mg, 59.8% for 30 mg) 1
- Skin clearance: 73% of patients achieved disease remission by 3 months 2
- Dose-dependent response: The 30 mg dose showed greater clinical benefit with 74% improvement in disease severity at 16 weeks versus 62% for 15 mg 2
Rheumatoid Arthritis
- Clinical response by week 2: Improvements in joint symptoms typically observed within 2 weeks 3
- Optimal response by 3 months: DAS28 remission rates reached 73% at 3 months in real-world data 4
- Steady-state achieved in 4 days: Drug concentrations reach therapeutic levels within 4 days of daily dosing 5
Ankylosing Spondylitis
- Response by week 2: Significant ASAS 40 response (52% vs 26% placebo) observed at the first post-baseline visit at week 2 3
- Slower than TNF inhibitors: Separation from placebo occurred at 4-8 weeks, suggesting a slower onset than TNF inhibitors 3
Inflammatory Bowel Disease (Ulcerative Colitis/Crohn's Disease)
- Induction phase: 8 weeks at 45 mg daily for initial response 3
- Extended induction if needed: Patients without response at 8 weeks may benefit from an additional 8 weeks (59% achieved response by week 16) 6
- Maintenance dosing: After induction, switch to 15 mg or 30 mg daily 6
Psoriatic Arthritis
- Similar timeline to RA: Clinical improvements typically within 2-4 weeks 3
- Peak response by 12-16 weeks: Maximal benefit achieved by 3-4 months
Important Clinical Considerations
What to Tell Patients
- Early itch relief (AD patients): Expect some improvement in itching within the first week, with continued improvement over the next month
- Joint symptoms (RA/PsA patients): Noticeable improvement typically within 2-4 weeks
- Full benefit takes time: Maximum therapeutic effect requires 12-16 weeks of continuous treatment
- Don't stop early: Discontinuing treatment leads to rapid loss of response within 4 weeks for skin clearance and within 5 days for itch 7
Dosing Strategy
The FDA-approved dosing varies by indication 5:
- RA/PsA/AS: 15 mg once daily
- Atopic Dermatitis: 15 mg or 30 mg once daily (30 mg for more severe disease)
- UC induction: 45 mg once daily for 8 weeks
- UC maintenance: 15 mg or 30 mg once daily
- Crohn's Disease induction: 45 mg once daily for 12 weeks
- Crohn's Disease maintenance: 15 mg or 30 mg once daily
Common Pitfall
Premature discontinuation: Patients may stop treatment before achieving maximal benefit. Emphasize that while early improvements occur within 1-2 weeks, full therapeutic effect requires 3-4 months of continuous treatment 1, 2.
Switching from Other Therapies
When switching from dupilumab to upadacitinib in AD patients, additional incremental improvements occur within 4 weeks of starting upadacitinib, with most patients achieving adequate response even if they failed dupilumab 8.